Severe EBV hepatitis treated with valganciclovir

R Pisapia; A Mariano; A Rianda; A Testa; A Oliva; L Vincenzi

doi:10.1007/s15010-012-0303-0

Severe EBV hepatitis treated with valganciclovir

Infection. 2013 Feb;41(1):251-4. doi: 10.1007/s15010-012-0303-0. Epub 2012 Jul 27.

Authors

R Pisapia¹, A Mariano, A Rianda, A Testa, A Oliva, L Vincenzi

Affiliation

¹ Clinical Department, First Division, National Institute for Infectious Diseases "Lazzaro Spallanzani", Via Portuense 292, 00149, Rome, Italy.

PMID: 22837057
DOI: 10.1007/s15010-012-0303-0

Abstract

We describe the case of an 18-year-old immunocompetent male patient with severe hepatitis during primary Epstein-Barr virus infection, treated with oral valganciclovir. During the initial therapy with corticosteroids, the patient's clinical condition and liver function worsened, so we decided to add oral valganciclovir for its good bio-availability and previous encouraging experiences in different clinical settings, with rapid resolution of the symptoms.

Publication types

Case Reports

MeSH terms

Adolescent
Antiviral Agents / administration & dosage
Antiviral Agents / therapeutic use*
Epstein-Barr Virus Infections / diagnosis
Epstein-Barr Virus Infections / drug therapy*
Ganciclovir / administration & dosage
Ganciclovir / analogs & derivatives*
Ganciclovir / therapeutic use
Hepatitis, Viral, Human / diagnosis
Hepatitis, Viral, Human / drug therapy*
Humans
Male
Treatment Outcome
Valganciclovir

Substances

Antiviral Agents
Valganciclovir
Ganciclovir